FrancophonIA/ELRC3.0 huggingface dataset:
English: Other information about Purevax RC:
Estonian: Muu teave vaktsiini Purevax RC kohta
English: Feline viral rhinotracheitis (live attenuated) and feline calicivirosis (inactivated) vaccine
Estonian: kasside viirusliku rinotrahheiidi (nõrgestatud elus-) ja kasside kalitsiviroosi (inaktiveeritud) vaktsiin
English: • feline calicivirosis (a flu-like illness with inflammation of the mouth caused by a calicivirus).
Estonian: • kasside kalitsiviroos (kalitsiviirusest põhjustatud gripilaadne haigus, millega kaasneb suupõletik).
English: How does Purevax RC work?
Estonian: Kuidas Purevax RC toimib?
English: What is the risk associated with Purevax RC?
Estonian: Mis riskid vaktsiiniga Purevax RC kaasnevad?
English: Purevax RC is available as a lyophilisate (freeze-dried pellet) and solvent that are made up into a suspension for injection.
Estonian: Vaktsiini Purevax RC turustatakse süstesuspensiooni lüofilisaadi (külmkuivatatud graanulid) ja lahustina.
English: How has Purevax RC been studied?
Estonian: Kuidas vaktsiini Purevax RC uuriti?
English: What is Purevax RC used for?
Estonian: Milleks vaktsiini Purevax RC kasutatakse?
English: What benefit has Purevax RC shown during the studies?
Estonian: Milles seisneb uuringute põhjal vaktsiini Purevax RC kasulikkus?
English: Invented name Strength Pharmaceutical Form Route of Administration
Estonian: Ravimi nimetus Tugevus Ravimvorm
English: Influenza virus surface antigens (haemagglutinin and neuraminidase)*, inactivated, of the following strains: A/California/7/2009 (H1N1)pdm09- like strain (A/Brisbane/10/2010, wild type)
Estonian: Gripiviiruse pinnaantigeenid (hemaglutiniin ja neuraminidaas)*, inaktiveeritud, sisaldavad järgmisi tüvesid: A/California/7/2009 (H1N1)pdm09 - sarnane tüvi (A/Brisbane/10/2010, metsik tüüp)
English: A/Switzerland/9715293/2013 (H3N2) - like strain (A/South Australia/55/2014, wild type)
Estonian: A/Switzerland/9715293/2013 (H3N2) - sarnane tüvi (A/South Australia/55/2014, metsik tüüp)
English: * propagated in Madin Darby Canine Kidney (MDCK) cells ** haemagglutinin
Estonian: * kultiveeritud Madin Darby Canine Kidney (MDCK) rakukultuuris ** hemaglutiniin
English: B/Phuket/3073/2013 - like strain (B/Utah/9/2014, wild type)
Estonian: B/Phuket/3073/2013 - sarnane tüvi (B/Utah/9/2014, metsik tüüp)
English: 2 x 10 pre-filled syringes (Luer Cone) + 20 needles
Estonian: 2 x 10 süstelit (Luer Cone) + 20 nõela
English: 10 pre-filled syringe (Luer Lock) + 10 needles l t o r
Estonian: 10 süstelit (Luer Lock) + 10 nõela l n a
English: 1 pre-filled syringe (Luer Lock) + 1 needle
Estonian: 1 süstel (Luer Lock) + 1 nõel
English: 2 x 10 pre-filled syringes (Luer Lock)
Estonian: 2 x 10 süstelit (Luer Lock)
English: 1 pre-filled syringe (Luer Lock)
Estonian: 1 süstel (Luer Lock)
English: 1 pre-filled syringe (Luer Cone)
Estonian: 1 süstel (Luer Cone)
English: 1 pre-filled syringe (Luer Cone) + 1 needle
Estonian: 1 süstel (Luer Cone) + 1 nõel
English: 2 x 10 pre-filled syringes (Luer Cone)
Estonian: 2 x 10 süstelit (Luer Cone)
English: 10 pre-filled syringes (Luer Cone) + 10 needles
Estonian: 10 süstelit (Luer Cone) + 10 nõela
English: 10 pre-filled syringes (Luer Lock)
Estonian: 10 süstelit (Luer Lock)
English: 10 pre-filled syringes (Luer Cone)
Estonian: 10 süstelit (Luer Cone)
English: Invented name Strength Pharmaceutical Form
Estonian: Tugevus Ravimvorm Manustamistee Pakendi iseloomustus Pakendi sisu
English: Following the European Commission Decision the Risk Management Plan should be submitted with any new application for extending the indication regarding the treatment of mania in bipolar disorder, as relevant.
Estonian: Euroopa Komisjoni otsuse kohaselt tuleb riskijuhtimiskava esitada kõikide uute taotluste korral, millega soovitakse laiendada näidustust seoses bipolaarse meeleoluhäire korral esineva maania raviga.
English: CONDITIONS OF THE MARKETING AUTHORISATIONS National Competent Authorities, coordinated by the Reference Member State where applicable, shall ensure that the following conditions are fulfilled by the Marketing Authorisation Holders:
Estonian: Riikide pädevad asutused, mida koordineerib viiteliikmesriik, kui see on asjakohane, tagavad, et müügiloa hoidjad täidavad järgmised tingimused.
English: ANNEX IV CONDITION OF THE MARKETING AUTHORISATIONS
Estonian: IV LISA MÜÜGILUBADE TINGIMUSED
English: This can result in serious vision loss and even blindness.
Estonian: Tagajärjeks võib olla tugev nägemislangus ja isegi pimedaks jäämine.
English: Further information on Rhokiinsa can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/rhokiinsa
Estonian: Lisateave Rhokiinsa kohta on ameti veebilehel: ema.europa.eu/medicines/human/EPAR/rhokiinsa
English: Rhokiinsa (netarsudil)
Estonian: Rhokiinsa (netarsudiil)
English: What measures are being taken to ensure the safe and effective use of Rhokiinsa?
Estonian: Mis meetmed võetakse, et tagada Rhokiinsa ohutu ja efektiivne kasutamine?
English: The safety of Rhokiinsa will be further investigated in a study.
Estonian: Rhokiinsa ohutust uuritakse veel ühes uuringus.
English: The European Medicines Agency therefore decided that Rhokiinsa's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et Rhokiinsa kasulikkus on suurem kui sellega kaasnevad riskid ja ravimi kasutamise võib ELis heaks kiita.
English: Other information about Rhokiinsa
Estonian: Muu teave Rhokiinsa kohta
English: As for all medicines, data on the use of Rhokiinsa are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, tehakse Rhokiinsa kasutamise kohta pidevat järelevalvet.
English: Why is Rhokiinsa authorised in the EU?
Estonian: Miks Rhokiinsa ELis heaks kiideti?
English: However, side effects on the eye were more frequent than those of timolol, and this may lead people to stop treatment.
Estonian: Silmades esines kõrvalnähte siiski sagedamini kui timolooliga ning see võib põhjustada ravi lõpetamist.
English: For more information about using Rhokiinsa, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Rhokiinsa kasutamise kohta saate pakendi infolehelt või küsige oma arstilt või apteekrilt.
English: Side effects reported with Rhokiinsa are carefully evaluated and any necessary action taken to protect patients.
Estonian: Rhokiinsa kõrvalnähte hinnatakse hoolikalt ja patsientide kaitseks võetakse vajalikke meetmeid.
English: Rhokiinsa (netarsudil) EMA/621772/2019
Estonian: Rhokiinsa (netarsudiil) EMA/521993/2019
English: In terms of safety, the side effects of Rhokiinsa are considered manageable and were more likely to be confined to the eye.
Estonian: Ohutuse seisukohast peeti Rhokiinsa kõrvalnähte hallatavateks ning suurema tõenäosusega silmaga piirduvateks.
English: What is Rhokiinsa and what is it used for?
Estonian: Mis on Rhokiinsa ja milleks seda kasutatakse?
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Rhokiinsa have been included in the summary of product characteristics and the package leaflet.
Estonian: Rhokiinsa ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: Rhokiinsa, which has a different mode of action from previously authorised treatments, provides another treatment option for patients with open-angle glaucoma and ocular hypertension.
Estonian: Rhokiinsa, millel on varem heakskiidetud ravimeetoditest erinev toimemehhanism, pakub avatud nurga glaukoomiga ja okulaarse hüpertensiooniga patsientidele veel üht ravivõimalust.
English: In patients with moderately high eye pressure (up to 25 mmHg), Rhokiinsa was as effective as timolol (another medicine), lowering the pressure by around 3.9 mmHg to 4.7 mmHg, compared with reductions of 3.8 mmHg to 5.2 mmHg for patients using timolol.
Estonian: Mõõdukalt suurenenud silmarõhuga (kuni 25 mmHg) patsientidel oli Rhokiinsa sama efektiivne kui timolool (samuti silmaravim), vähendades rõhku ligikaudu 3,9 mmHg - 4,7 mmHg võrra, samas kui timolooli kasutavatel patsientidel vähenes rõhk 3,8 mmHg - 5,2 mmHg võrra.
English: However, when these results were combined with results from other studies, decreases in eye pressure with Rhokiinsa were larger than those seen in the main study only.
Estonian: Kui need tulemused kombineeriti muude uuringute tulemustega, vähenes Rhokiinsa kasutamisel silmarõhk siiski rohkem kui üksnes põhiuuringut arvestades.
English: The effect of Rhokiinsa was less pronounced in patients whose eye pressure was more than 30 mmHg, but these results were considered less important because Rhokiinsa is not expected to be used on its own in this group.
Estonian: Rhokiinsa toime oli vähem väljendunud patsientidel, kellel silmarõhk oli üle 30 mmHg, kuid neid tulemusi peeti vähem oluliseks, sest Rhokiinsat ei kasutata eeldatavalt selles rühmas ainuravimina.
English: Other common side effects (which may affect up to 2 in 10 people) are: cornea verticillata (deposits in the cornea, the transparent layer in front of the eye that covers the pupil and iris), eye pain, conjunctival haemorrhage (bleeding in the surface layer of the eye), erythema (reddening) at the site where the medicine was applied and the eyelid, corneal staining, blurred vision and increased lacrimation (watery eyes).
Estonian: Muud sagedad kõrvalnähud (võivad esineda kuni 2 patsiendil 10st) on: cornea verticillata ehk sarvkesta hägusus (ladestused pupilli ja vikerkesta katvas läbipaistvas kelmes - sarvkestas), silmavalu, konjunktiivi hemorraagia (silma pindmise kihi verejooks), ravimi manustamiskoha ja silmalau erüteem (punetus), sarvkesta värvumine, nägemise hägustumine ja suurenenud pisaravoolus (vesised silmad).
English: A main study of 708 patients with open-angle glaucoma or ocular hypertension showed that Rhokiinsa is effective at lowering eye pressure.
Estonian: Põhiuuringus, milles osales 708 avatud nurga glaukoomiga või okulaarse hüpertensiooniga patsienti, tõendati, et Rhokiinsa on silmarõhu alandamisel efektiivne.
English: What are the risks associated with Rhokiinsa?
Estonian: Mis riskid Rhokiinsaga kaasnevad?
English: Rhokiinsa is an eye-drop solution that is used to reduce pressure inside the eye in adults who have open-angle glaucoma (a disease where the pressure in the eye rises because fluid cannot drain out of the eye) or ocular hypertension (when the pressure in the eye is higher than normal).
Estonian: Rhokiinsa on silmatilgalahus, mida kasutatakse silma siserõhu vähendamiseks täiskasvanutel, kellel on avatud nurga glaukoom (haigus, mille korral silma siserõhk suureneb, sest vedelik ei pääse silmast välja) või okulaarne hüpertensioon (silma siserõhk on normist suurem).
English: In patients whose eye pressure was higher than 25 mmHg, Rhokiinsa was less effective than timolol.
Estonian: Patsientidel, kellel silmarõhk oli üle 25 mmHg, oli Rhokiinsa vähem efektiivne kui timolool.
English: The active substance in Rhokiinsa, netarsudil, is a Rho kinase inhibitor.
Estonian: Rhokiinsa toimeaine netarsudiil on Rho-kinaasi inhibiitor.
English: Rhokiinsa contains the active substance netarsudil.
Estonian: Rhokiinsa sisaldab toimeainena netarsudiili.
English: How is Rhokiinsa used?
Estonian: Kuidas Rhokiinsat kasutatakse?
English: Rhokiinsa showed good effects across a range of eye pressures.
Estonian: Rhokiinsa toimis hästi mitmesuguste silmarõhkude korral.
English: The most common side effect with Rhokiinsa (which may affect around 5 in 10 people) is conjunctival hyperaemia (increased blood supply to the eye, leading to redness).
Estonian: Rhokiinsa kõige sagedam kõrvalnäht (võib esineda ligikaudu 5 patsiendil 10st) on konjunktiivi (silma sidekesta) hüpereemia (silma suurenenud verevarustus, mis põhjustab silma punetust).
English: For the full list of side effects and restrictions with Rhokiinsa, see the package leaflet.
Estonian: Rhokiinsa kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: Rhokiinsa is only available on prescription and should be started by an eye specialist.
Estonian: Rhokiinsa on retseptiravim ja ravi sellega peab alustama silmaarst.
English: When pressure in the eye is raised, it can cause damage to the retina (the light-sensitive membrane at the back of the eye) and to the optic nerve that sends signals from the eye to the brain.
Estonian: Silma siserõhu suurenemine võib kahjustada võrkkesta (valgustundlik kelme silma tagaosas) ja silmanärvi, mille kaudu liiguvad närvisignaalid silmast ajju.
English: What benefits of Rhokiinsa have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Rhokiinsa kasulikkus?
English: How does Rhokiinsa work?
Estonian: Kuidas Rhokiinsa toimib?
English: When it blocks this enzyme, Rhokiinsa increases the flow of fluid out of the eyeball, thereby lowering pressure inside the eye. Rhokiinsa is also thought to lower eye pressure by reducing pressure in the veins around the eyes.
Estonian: Blokeerides seda ensüümi, suurendab Rhokiinsa vedeliku väljavoolu silmamunast, alandades seega silma siserõhku.
English: This means that it blocks the activity of an enzyme called Rho kinase, which has a role in controlling drainage of fluid from the eye.
Estonian: See blokeerib vedeliku drenaaži silmast reguleeriva ensüümi (Rho-kinaasi) aktiivsuse.
English: It is available as an eye-drop solution (200 microgram/ml) and the dose is one drop in the affected eye once a day, in the evening.
Estonian: Ravimi annus on 1 tilk kahjustatud silma 1 kord ööpäevas õhtuti.
English: An overview of Rhokiinsa and why it is authorised in the EU
Estonian: Ülevaade ravimist Rhokiinsa ja ELis müügiloa väljastamise põhjendus
English: 1 bottle; 2 sachets
Estonian: 1 pudel; 2 kotikest
English: 1 bottle; 1 sachet
Estonian: 1 pudel; 1 kotike
English: ATCvet code: QI06AJ03.
Estonian: ATCvet kood: QI06AJ03
English: Date of first authorisation: 23/02/2005 Date of last renewal: 14/01/2010
Estonian: Esmase müügiloa väljastamise kuupäev : 23/02/2005 Müügiloa pikendamise kuupäev: 14/01/2010
English: Store and transport refrigerated (2 °C - 8 °C).
Estonian: Hoida ja transportida külmas (2° C - 8° C).
English: Laboratoire Porte des Alpes Rue de l'Aviation
Estonian: Laboratory of Lyon Porte des Alpes Rue de l´aviation
English: Active immunisation of cats aged 8 weeks and older: - against feline viral rhinotracheitis to reduce clinical signs, - against calicivirus infection to reduce clinical signs, - against Chlamydophila felis infection to reduce clinical signs, - against feline panleucopenia to prevent mortality and clinical signs.
Estonian: 8-nädalaste ja vanemate kassipoegade aktiivne immuniseerimine: - kasside viraalse rinotrahheiidi vastu, et vähendada kliinilisi tunnuseid - kalitsiviirusinfektsiooni vastu , et vähendada kliinilisi tunnuseid - Chlamydophila felis vastu, et vähendada kliinilisi tunnuseid - kasside panleukopeenia vastu, et ära hoida suremust ja kliinilisi tunnuseid
English: EU/2/04/050/001 Lyophilisate (10 bottles of 1 dose) + solvent (10 bottles of 1 ml) EU/2/04/050/002 Lyophilisate (50 bottles of 1 dose) + solvent (50 bottles of 1 ml)
Estonian: EU/2/04/050/001 lüofilisaat (10 pudelit, igas 1 doos) + lahusti (10 pudelit, igas 10 ml) EU/2/04/050/002 lüofilisaat (50 pudelit, igas 1 doos) + lahusti (50 pudelit, igas 10 ml)
English: Lyophilisate (10xdose) + solvent (10x1 ml) Lyophilisate (50x1 dose) + solvent (50x1 ml)
Estonian: Lüofilisaat (10 x 1 doos) + lahus (10 x 1 ml) Lüofilisaat (50 x 1 doos) + lahus (50 x 1 ml)
English: Revaccination: - the first revaccination must be carried out for all components one year after the primary vaccination course, - subsequent revaccinations must be carried out: every year for the chlamydiosis component and at intervals of up to three years for the rhinotracheitis, calicivirosis and panleucopenia components.
Estonian: Kordusvaktsineerimine: - esimene kordusvaktsineerimine kõigi komponentide suhtes: üks aasta pärast esmavaktsineerimist, - järgnevad kordusvaktsineerimised tuleb läbi viia igal aastal klamüdioosi komponendi suhtes ning intervalliga kuni kolm aastat rinotrahheiidi, kalitsiviroosi ja panleukopeenia komponentide suhtes.
English: 1 cell culture infective dose 50%
Estonian: 1 ml 1 rakukultuuri infektiivne doos 50%
English: Safety and efficacy data are available which demonstrate that this vaccine can be mixed and administered with Merial non-adjuvanted vaccine against feline leukaemia and/or administered the same day but not mixed with Merial adjuvanted vaccine against rabies.
Estonian: Olemasolevad ohutuse ja efektiivsuse andmed, mis näitavad, et antud vaktsiinipreparaati võib segada ja manustada koos Meriali mitteadjuveeritud vaktsiiniga kasside leukeemia vastu ja/või manustada samal päeval kuid mitte kokku segatuna Meriali adjuveeritud marutaudi vastase vaktsiiniga.
English: The duration of immunity after the last re-vaccination is 3 years for the rhinotracheitis, calicivirosis and panleucopenia components, and 1 year for the Chlamydophila felis component.
Estonian: Imuunsuse kestus pärast viimast (re)vaktsineerimist on rinotrahheiidi, kalitsiviiruse, ja panleukopeenia komponentide suhtes 3 aastat ning Chlamydophila felis komponendi suhtes 1 aasta.
English: Per dose of 1 ml: FHV (F2 strain) ................................................................................................................. ≥ 104.9 CCID50
Estonian: 1 ml doos sisaldab: FHV (tüvi F2) ..................................................................................................................... ≥ 104.9 CCID50
English: Attenuated feline rhinotracheitis herpesvirus (FHV F2 strain) ....................................... ≥ 104.9 CCID501 Inactivated feline calicivirus (FCV 431 and G1 strains) antigens ................................... ≥ 2.0 ELISA U. Attenuated Chlamydophila felis (905 strain) ...................................................................... ≥ 103.0 EID502 Attenuated feline panleucopenia virus (PLI IV) ............................................................. ≥ 103.5 CCID501
Estonian: Kasside nõrgestatud rinotrahheiidi herpesviirus (FHV F2 tüvi) ..................................... ≥ 104.9 CCID501 Kasside inaktiveeritud kalitsiviirus (FCV 431 ja G1 tüvi) antigeenid ........................... ≥ 2.0 ELISA U. Nõrgestatud Chlamydophila felis (905 tüvi) ...................................................................... ≥ 103.0 EID502 Kasside nõrgestatud panleukopeenia viirus (PLI IV) ..................................................... ≥ 103.5 CCID501
English: Where high levels of maternal antibodies against rhinotracheitis, calicivirosis, panleucopenia or Chlamydophila components are expected to be present (e.g. in kittens of 9-12 weeks of age borne from queens which were vaccinated before pregnancy and/or with known or suspected previous exposure to the pathogen(s)), the primary vaccination course should be delayed until 12 weeks of age.
Estonian: 9-12 nädala vanused kassipojad, kelle emad on vaktsineeritud enne tiinestumistja/või teadaolev või kahtlustatav kokkupuude patogeeni(de)ga) tuleks esmase vaktsineerimiskuuri algus lükata edasi kuni 12. elunädalani.
English: Type I glass bottle containing 1 dose of lyophilisate and type I glass bottle containing 1 ml solvent, both closed with a butyl elastomer closure and sealed with an aluminium or plastic cap.
Estonian: Viaal on suletud butüül-elsatomeerist korgiga, mis on kaetud alumiinium- või plastikkapsliga.
English: Active substances:
Estonian: TOIMEAINE SISALDUS
English: Onsets of immunity have been demonstrated 1 week after primary vaccination course for rhinotracheitis, calicivirus, Chlamydophila felis and panleucopenia components.
Estonian: Immuunsus tekib 1 nädal pärast esmast vaktsineerimiskuuri rinotrahheiidi, kalitsiviiruse, Chlamydophila felis ja panleukopeenia vastu.
English: Store and transport refrigerated.
Estonian: Hoida ja transportida külmas Hoida kaitstult valguse eest.
English: Stimulates active immunity against feline rhinotracheitis herpesvirus, feline calicivirus, Chlamydophila felis and feline panleucopenia virus.
Estonian: Kutsub esile immuunsuse kasside rinotrahheiiti põhjustava herpesviiruse, kasside kalitsiviiruse, Chlamydophila felis ja kasside panleukopeenia vastu.
English: Gentamicin, at most .......................................................................................................................... 28 µg
Estonian: Gentamütsiin maksimaalselt ............................................................................................................ 28 µg
English: PACKAGE LEAFLET FOR: Purevax RCPCh lyophilisate and solvent for suspension for injection
Estonian: PAKENDI INFOLEHT Purevax RCPCh lüofilisaat ja lahusti süstesuspensiooni valmistamiseks
English: Water for injections ..................................................................................................................... q.s.
Estonian: Süstevesi ......................................................................................................................................q.s.
English: Purevax RCPCh lyophilisate and solvent for suspension for injection
Estonian: Purevax RCPCh Lüofilisaat ja lahusti süstesuspensiooni valmistamiseks
English: Purevax RCPCh Lyophilisate and solvent for suspension for injection.
Estonian: Purevax RCPCh lüofilisaat ja lahusti süstesuspensiooni valmistamiseks
English: THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable
Estonian: KASUTAMISEKS VABASTAMISE EEST VASTUTAV TOOTJA B. HANKE- JA KASUTAMISTINGIMUSED VÕI PIIRANGUD C. RAVIMJÄÄKIDE PIIRNORMID
English: Per dose of 1 ml: Lyophilisate:
Estonian: Lüofilisaat: Toimeaine(d)::
English: However, the same EFSA document also states that:
Estonian: Samas EFSA dokumendis on märgitud ka järgmist:
English: Therefore this indication was removed.
Estonian: Seetõttu otsustati see näidustus kustutada.
English: <Invented name>
Estonian: <Väljamõeldud nimetus>
English: This is stated in the Regulation (EC) No 2160/20039 and based on the EFSA Opinion (2004)11.
Estonian: See on sätestatud komisjoni määruses (EÜ) nr 2160/20039 ja põhineb EFSA arvamusel (2004)11.
English: Lyskær 3E, 2 tv.
Estonian: Danmark A/S Lyskær 3E, 2 tv.
English: A disease shall be included on the list if it has been assessed in accordance with Article 7.
Estonian: Haigus lisatakse nimekirja pärast seda, kui seda on hinnatud artikli 7 alusel.
English: and Campylobacter spp.
Estonian: ja Campylobacter spp.
English: Mortality was the principal criteria for efficacy.
Estonian: Efektiivsuse põhikriteeriumiks oli suremus.
English: QUALITATIVE AND QUANTITATIVE COMPOSITION 1 g contains:
Estonian: KVALITATIIVNE JA KVANTITATIIVNE KOOSTIS 1 g sisaldab:
English: Medicated water must be renewed every 24 hours.
Estonian: Ravimvett tuleb vahetada iga 24 tunni järel.
English: • The restriction of the indications to those that are adequately substantiated by efficacy data;
Estonian: • näidustused piiratakse nendega, mida efektiivsusandmed piisavalt toetavad;
English: This evaluation focuses on issues with regard to the harmonisation that may change the benefit-risk balance.
Estonian: Hindamises keskendutakse ühtlustamisega seotud küsimustele, mis võivad muuta kasulikkuse ja riski tasakaalu.
English: The harmonisation of withdrawal periods was based on the better conducted and most reliable studies.
Estonian: Keeluaegade ühtlustamise aluseks valiti paremini korraldatud ja kõige usaldusväärsemad uuringud.
English: Drinking systems should be clean and free of rust to avoid reduction of activity.
Estonian: Joogiveesüsteem peab olema puhas ja roostest vaba, et mitte vähendada ravimi aktiivsust.
English: 92200 Neuilly Sur Seine
Estonian: 92200 Neuilly
English: Any use in exceptional circumstances on animal health and welfare grounds must recognize the consequences for public health.
Estonian: Mis tahes kasutamisel erandlikel asjaoludel loomade tervise ja heaolu põhjendusel tuleb arvestada võimalike tagajärgedega rahvatervisele.
English: EFSA (European Food Safety Authority) and ECDC (European Centre for Disease Prevention and Control), 2016.
Estonian: 4 EFSA (European Food Safety Authority) and ECDC (European Centre for Disease Prevention and Control), 2016. The